{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:54Z","timestamp":1789584894464,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00259-022-05792-y","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T08:02:56Z","timestamp":1651564976000},"page":"3841-3851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy"],"prefix":"10.1007","volume":"49","author":[{"given":"Aleksandra","family":"Sygu\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Ledwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"Hasse-Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Jurecka-Lubieniecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Michalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Paliczka-Cie\u015blik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Chmielik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Sczasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jarzab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-2880","authenticated-orcid":false,"given":"Daria","family":"Handkiewicz-Junak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"5792_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-007-0443-2","author":"JC Reubi","year":"2007","unstructured":"Reubi JC. Peptide receptor expression in GEP-NET [eng]. Virchows Arch. 2007;451 Suppl 1:S47\u2013S50.\u00a0https:\/\/doi.org\/10.1007\/s00428-007-0443-2.","journal-title":"Virchows Arch"},{"key":"5792_CR2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529209000106","author":"H Ahlman","year":"1992","unstructured":"Ahlman H, W\u00e4ngberg B, Nilsson O, Grimelius L, Gran\u00e9rus G, Modlin IM, et al. Aspects on diagnosis and treatment of the foregut carcinoid syndrome [eng]. Scand J Gastroenterol. 1992;27:59\u201371.\u00a0https:\/\/doi.org\/10.3109\/00365529209000106.","journal-title":"Scand J Gastroenterol"},{"key":"5792_CR3","doi-asserted-by":"publisher","DOI":"10.1159\/000183751","author":"K Oberg","year":"2009","unstructured":"Oberg K, Ferone D, Kaltsas G, Knigge U-P, Taal B, Pl\u00f6ckinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy [eng]. Neuroendocrinology. 2009;90:09\u2013213.\u00a0https:\/\/doi.org\/10.1159\/000183751.","journal-title":"Neuroendocrinology"},{"issue":"24 Pt 1","key":"5792_CR4","first-page":"6977","volume":"48","author":"AV Schally","year":"1988","unstructured":"Schally AV. Oncological applications of somatostatin analogues [eng]. Cancer Res. 1988;48(24 Pt 1):6977\u201385.","journal-title":"Cancer Res"},{"key":"5792_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)02082-t","author":"YC Patel","year":"1995","unstructured":"Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family [eng]. Life Sci. 1995;57:9\u201365.\u00a0https:\/\/doi.org\/10.1016\/0024-3205(95)02082-t.","journal-title":"Life Sci"},{"key":"5792_CR6","doi-asserted-by":"publisher","DOI":"10.4065\/80.4.502","author":"T Delaunoit","year":"2005","unstructured":"Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors [eng]. Mayo Clin Proc. 2005;80:502\u20136.\u00a0https:\/\/doi.org\/10.4065\/80.4.502.","journal-title":"Mayo Clin Proc"},{"key":"5792_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900501)65:9<1883::aid-cncr2820650902>3.0.co;2-3","author":"B Eriksson","year":"1990","unstructured":"Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors [eng]. Cancer. 1990;65:1883\u201390.\u00a0https:\/\/doi.org\/10.1002\/1097-0142(19900501)65:9%3c1883::aid-cncr2820650902%3e3.0.co;2-3.","journal-title":"Cancer"},{"key":"5792_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00073-9","author":"T Aparicio","year":"2001","unstructured":"Aparicio T, Ducreux M, Baudin E, Sabourin JC, de Baere T, Mitry E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours [eng]. Eur J Cancer. 2001;37:1014\u20139.\u00a0https:\/\/doi.org\/10.1016\/s0959-8049(01)00073-9.","journal-title":"Eur J Cancer"},{"key":"5792_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/annonc\/mdf142","volume":"13","author":"M Hejna","year":"2002","unstructured":"Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol. 2002;13:653\u201368.\u00a0https:\/\/doi.org\/10.1093\/annonc\/mdf142.","journal-title":"Ann Oncol"},{"key":"5792_CR10","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group [eng]. J Clin Oncol. 2009;27:4656\u20133.\u00a0https:\/\/doi.org\/10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"key":"5792_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors [eng]. N Engl J Med. 2014;371:224\u201333.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1316158.","journal-title":"N Engl J Med"},{"key":"5792_CR12","doi-asserted-by":"publisher","DOI":"10.1053\/snuc.2002.31027","author":"M de Jong","year":"2002","unstructured":"de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WAP, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings [eng]. Semin Nucl Med. 2002;32:133\u201340.\u00a0https:\/\/doi.org\/10.1053\/snuc.2002.31027.","journal-title":"Semin Nucl Med"},{"key":"5792_CR13","doi-asserted-by":"publisher","unstructured":"Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history [eng]. Ann N Y Acad Sci. 1994;733:496\u2013506.\u00a0https:\/\/doi.org\/10.1111\/j.1749-6632.1994.tb17300.x.","DOI":"10.1111\/j.1749-6632.1994.tb17300.x"},{"key":"5792_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/bip.10349","author":"G Paganelli","year":"2002","unstructured":"Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies [eng]. Biopolymers. 2002;66:393\u20138.\u00a0https:\/\/doi.org\/10.1002\/bip.10349.","journal-title":"Biopolymers"},{"key":"5792_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors [eng]. N Engl J Med. 2017;376:125\u201335.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"5792_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4112","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar AE, et al. Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J Clin Oncol.\u00a02021;39:4112.\u00a0https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4112.","journal-title":"J Clin Oncol"},{"key":"5792_CR17","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.\u00a0https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"5792_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0142-y","author":"SM Bison","year":"2015","unstructured":"Bison SM, Haeck JC, Bol K, Koelewijn SJ, Groen HC, Melis M, et al. Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies [eng]. EJNMMI Res. 2015;5:62.\u00a0https:\/\/doi.org\/10.1186\/s13550-015-0142-y.","journal-title":"EJNMMI Res"},{"key":"5792_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1631-x","author":"PG Claringbold","year":"2011","unstructured":"Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours [eng]. Eur J Nucl Med Mol Imaging. 2011;38:302\u201311.\u00a0https:\/\/doi.org\/10.1007\/s00259-010-1631-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5792_CR20","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1276","author":"PG Claringbold","year":"2012","unstructured":"Claringbold PG, Price RA, Turner JH. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors [eng]. Cancer Biother Radiopharm. 2012;27561\u20139.\u00a0https:\/\/doi.org\/10.1089\/cbr.2012.1276.","journal-title":"Cancer Biother Radiopharm"},{"key":"5792_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002532","author":"A Yordanova","year":"2019","unstructured":"Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, et al. Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors [eng]. Clin Nucl Med. 2019;44:e329\u2013e335.\u00a0https:\/\/doi.org\/10.1097\/RLU.0000000000002532.","journal-title":"Clin Nucl Med"},{"key":"5792_CR22","doi-asserted-by":"publisher","unstructured":"Purohit NK, Shah RG, Adant S, Hoepfner M, Shah GM, Beauregard J-M. Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor [eng]. Oncotarget. 2018;9:24694\u2013706.\u00a0https:\/\/doi.org\/10.18632\/oncotarget.25266.","DOI":"10.18632\/oncotarget.25266"},{"key":"5792_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67199-9","author":"C Cullinane","year":"2020","unstructured":"Cullinane C, Waldeck K, Kirby L, Rogers BE, Eu P, Tothill RW, et al. Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP [eng]. Sci Rep. 2020;10:10169.\u00a0https:\/\/doi.org\/10.1038\/s41598-020-67199-9.","journal-title":"Sci Rep"},{"issue":"5","key":"5792_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40336-019-00342-3","volume":"7","author":"SA Pignata","year":"2019","unstructured":"Pignata SA, Ferrantelli A, Baldari S. Peptide receptor radionuclide therapy plus somatostatin analogues for a neuroendocrine tumour combined and maintenance treatment. Clinical and Translational Imaging. 2019;7(5):373\u20136.","journal-title":"Clinical and Translational Imaging"},{"key":"5792_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30323-5","author":"L Bodei","year":"2020","unstructured":"Bodei L, Sch\u00f6der H, Baum RP, Herrmann K, Strosberg J, Caplin M, et al. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy [eng]. Lancet Oncol. 2020;21:e431\u2013e443.\u00a0https:\/\/doi.org\/10.1016\/S1470-2045(20)30323-5.","journal-title":"Lancet Oncol"},{"key":"5792_CR26","doi-asserted-by":"publisher","unstructured":"Aalbersberg EA, de Wit-van der Veen, B J, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, et al. Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation [eng]. Eur J Nucl Med Mol Imaging. 2019;46:696\u2013703.\u00a0https:\/\/doi.org\/10.1007\/s00259-018-4117-x.","DOI":"10.1007\/s00259-018-4117-x"},{"key":"5792_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, H\u00f6rsch D, O\u2019Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours [eng]. Eur J Nucl Med Mol Imaging. 2013;40:800\u201316.\u00a0https:\/\/doi.org\/10.1007\/s00259-012-2330-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5792_CR28","doi-asserted-by":"publisher","unstructured":"Pl\u00f6ckinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy [eng]. Best Pract Res Clin Endocrinol Metab. 2007;21:45\u201362.\u00a0https:\/\/doi.org\/10.1016\/j.beem.2007.01.002.","DOI":"10.1016\/j.beem.2007.01.002"},{"key":"5792_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04083.x","author":"C Toumpanakis","year":"2009","unstructured":"Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR [eng]. Aliment Pharmacol Ther. 2009;30:733\u201340.\u00a0https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04083.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"5792_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123049","author":"AK Stueven","year":"2019","unstructured":"Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future [eng]. Int J Mol Sci. 2019;20.\u00a0https:\/\/doi.org\/10.3390\/ijms20123049.","journal-title":"Int J Mol Sci"},{"key":"5792_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, Peeters M, H\u00f6rsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study [eng]. Lancet. 2011;378:2005\u201312.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(11)61742-X.","journal-title":"Lancet"},{"key":"5792_CR32","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-10-0334","author":"F Gatto","year":"2011","unstructured":"Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors [eng]. Endocr Relat Cancer. 2011;18:R223\u201351.\u00a0https:\/\/doi.org\/10.1530\/ERC-10-0334.","journal-title":"Endocr Relat Cancer"},{"key":"5792_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/524130","author":"S Oh","year":"2011","unstructured":"Oh S, Prasad V, Lee DS, Baum RP, Chen X. Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intraindividual comparison of Ga-68 DOTANOC PET\/CT and F-18 FDG PET\/CT. Int J Mol Imaging. 2011;2011524130.\u00a0https:\/\/doi.org\/10.1155\/2011\/524130.","journal-title":"Int J Mol Imaging"},{"key":"5792_CR34","doi-asserted-by":"publisher","DOI":"10.7150\/thno.51215","author":"D Feijtel","year":"2021","unstructured":"Feijtel D, Doeswijk GN, Verkaik NS, Haeck JC, Chicco D, Angotti C, et al. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response [eng]. Theranostics. 2021;11:491\u2013505.\u00a0https:\/\/doi.org\/10.7150\/thno.51215.","journal-title":"Theranostics"},{"key":"5792_CR35","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0219","author":"A Sowa-Staszczak","year":"2017","unstructured":"Sowa-Staszczak A, Stefanska A, Chrapczynski P, Trofimiuk-M\u00fcldner M, Szura M, Hubalewska-Dydejczyk A. Does combination of \u201ccold\u201d and \u201chot\u201d somatostatin analogs prolong survival of patients with neuroendocrine neoplasms? [eng]. Endocr J. 2017;64:171\u20137.\u00a0https:\/\/doi.org\/10.1507\/endocrj.EJ16-0219.","journal-title":"Endocr J"},{"key":"5792_CR36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0947","author":"A Yordanova","year":"2018","unstructured":"Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy [eng]. Clin Cancer Res. 2018;24:4672\u201379.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0947.","journal-title":"Clin Cancer Res"},{"key":"5792_CR37","doi-asserted-by":"publisher","DOI":"10.3109\/02841869309083912","author":"LK Kvols","year":"1993","unstructured":"Kvols LK, Reubi JC. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol. 1993;32:197\u2013201.\u00a0https:\/\/doi.org\/10.3109\/02841869309083912.","journal-title":"Acta Oncol"},{"key":"5792_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.2.279","author":"P Ruszniewski","year":"1996","unstructured":"Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39:279.\u00a0https:\/\/doi.org\/10.1136\/gut.39.2.279.","journal-title":"Gut"},{"key":"5792_CR39","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0490","author":"ME Caplin","year":"2016","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study [eng]. Endocr Relat Cancer. 2016;23:191\u20139.\u00a0https:\/\/doi.org\/10.1530\/ERC-15-0490.","journal-title":"Endocr Relat Cancer"},{"key":"5792_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.11.034","author":"I Sullivan","year":"2017","unstructured":"Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, et al. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids [eng]. Eur J Cancer. 2017;75:59\u201367.\u00a0https:\/\/doi.org\/10.1016\/j.ejca.2016.11.034.","journal-title":"Eur J Cancer"},{"key":"5792_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.669484","author":"E Lenotti","year":"2021","unstructured":"Lenotti E, Alberti A, Spada F, Amoroso V, Maisonneuve P, Grisanti S, et al. Outcome of patients with metastatic lung neuroendocrine tumors submitted to first line monotherapy with somatostatin analogs [eng]. Front Endocrinol (Lausanne). 2021;12:669484.\u00a0https:\/\/doi.org\/10.3389\/fendo.2021.669484.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5792_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx078","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, Ruszniewski P, van Cutsem E, Lombard-Bohas C, Valle JW, de Herder WW, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial [eng]. Ann Oncol. 2017;28:1309\u201315.\u00a0https:\/\/doi.org\/10.1093\/annonc\/mdx078.","journal-title":"Ann Oncol"},{"key":"5792_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30681-2","author":"P Ferolla","year":"2017","unstructured":"Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial [eng]. Lancet Oncol. 2017;18:1652\u201364.\u00a0https:\/\/doi.org\/10.1016\/S1470-2045(17)30681-2.","journal-title":"Lancet Oncol"},{"key":"5792_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States [eng]. JAMA Oncol. 2017;3:1335\u201342.\u00a0https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"key":"5792_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082502","author":"S Levy","year":"2020","unstructured":"Levy S, van Veenendaal LM, Korse CM, Breekveldt ECH, Verbeek WHM, Vriens MR, et al. Survival in patients with neuroendocrine tumours of the small intestine: nomogram validation and predictors of survival [eng]. J Clin Med. 2020;9.\u00a0https:\/\/doi.org\/10.3390\/jcm9082502.","journal-title":"J Clin Med"},{"key":"5792_CR46","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0248","author":"L Chen","year":"2022","unstructured":"Chen L, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin M, Navalkissoor S. Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate [eng]. Endocr Relat Cancer. 2022;29:111\u201320.\u00a0https:\/\/doi.org\/10.1530\/ERC-21-0248.","journal-title":"Endocr Relat Cancer"},{"key":"5792_CR47","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0269","author":"V Marotta","year":"2018","unstructured":"Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame [eng]. Endocr Relat Cancer. 2018;25:R11\u2013R29.\u00a0https:\/\/doi.org\/10.1530\/ERC-17-0269.","journal-title":"Endocr Relat Cancer"},{"key":"5792_CR48","doi-asserted-by":"publisher","unstructured":"Bodei L, Kidd MS, Singh A, van der Zwan, Wouter A, Severi S, Drozdov IA, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest [eng]. Eur J Nucl Med Mol Imaging. 2020;47:895\u2013906. https:\/\/doi.org\/10.1007\/s00259-019-04601-3.","DOI":"10.1007\/s00259-019-04601-3"},{"key":"5792_CR49","doi-asserted-by":"publisher","DOI":"10.1159\/000443167","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site [eng]. Neuroendocrinology. 2016;103:172\u201385.\u00a0https:\/\/doi.org\/10.1159\/000443167.","journal-title":"Neuroendocrinology"},{"key":"5792_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [eng]. Ann Oncol. 2020;31:844\u201360.\u00a0https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol"},{"key":"5792_CR51","doi-asserted-by":"publisher","DOI":"10.1159\/000182196","author":"G Kl\u00f6ppel","year":"2009","unstructured":"Kl\u00f6ppel G, Couvelard A, Perren A, Komminoth P, McNicol A-M, Nilsson O, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification [eng]. Neuroendocrinology. 2009;90:162\u20136.\u00a0https:\/\/doi.org\/10.1159\/000182196.","journal-title":"Neuroendocrinology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05792-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05792-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05792-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T07:09:51Z","timestamp":1661238591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05792-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5792"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05792-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BJ received travel grants and speaker honoraria from Ipsen, Novartis; DH-J received travel grants and speaker honoraria from Ipsen, Novartis, and Teva; KHL and BJ-L received travel grants from Ipsen; other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the institutional Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}